Merck Announces Completion of Organon & Co. Spinoff
Merck known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. . “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Rob Davis, president, Merck. “With … Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Rob Davis, president, Merck. “With leadership in our growth pillars and our robust pipeline, Merck is well positioned for stron
This Combination Vaccine May Simplify Execution and Reduce Shots Needed to Complete CDC’s Recommended Child and Adolescent Immunization Schedule VAXELIS™ developed as part of a U.S.-based partnership between Merck known as MSD outside the United States and Canada, and Sanofi Pasteur, the global vaccines business unit of Sanofi, is now available in the U.S. VAXELIS is the first and only hexavalent combination .